CXCL8 and gastroesophageal reflux disease: Future in vitro work is warranted to address amprenavir protection against additional pepsin-induced molecular changes harboring a strong correlation with GERD severity and/or EAC, such as IL-8 and PTGS2/COX-2, and cancer-related cellular processes known to be impacted by pepsin such as cell-cycle regulation.